Letters

Advertisement for toremifene

BMJ 1996; 313 doi: https://doi.org/10.1136/bmj.313.7062.944b (Published 12 October 1996) Cite this as: BMJ 1996;313:944

Playing on women's fears is unethical

  1. Chris Twelves, Senior lecturer in medical oncology,
  2. Adrian Harnett, Consultant clinical oncologist
  1. Beatson Oncology Centre, Western Infirmary, Glasgow G11 6NT

    EDITOR,—We are concerned by the advertisement for Fareston (toremifene) published in the clinical research edition of the BMJ on 6 July (between p 24 and p 25) and in other clinical journals. The advertisement focuses on patients' perceived concerns about the toxicity of tamoxifen—specifically, its carcinogenic potential—and proposes toremifene as an alternative that could allay those fears. The issue of endometrial cancer and tamoxifen has stimulated much debate.1 It should, however, be seen in context. The national surgical adjuvant …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe